NCT07063745 2026-03-17
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
Clinical Trials
11 trialsNCT07463313 2026-03-11
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Not yet recruiting
NCT07365319 2026-01-26
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Not yet recruiting
NCT07318883 2026-01-06
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT06214572 2025-04-11
RUGB
Tata Memorial Centre
Phase 2/3 Recruiting
NCT06861777 2025-03-11
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT05254171 2024-11-06
ASPIRE
Panbela Therapeutics, Inc.
Phase 2/3 Recruiting
NCT04435652 2020-06-17
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed
NCT01204437 2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3 Completed